Secondary FSGS?!?

Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis | NEJM Cardiovascular disease is the leading cause of death in patients receiving hemodialysis, yet effective preventive therapies remain limited. Supplementation with n−3 polyunsaturated fatty acids, esp...

Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis | New England Journal of Medicine www.nejm.org/doi/full/10....

Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis | NEJM Cardiovascular disease is the leading cause of death in patients receiving hemodialysis, yet effective preventive therapies remain limited. Supplementation with n−3 polyunsaturated fatty acids, esp...

Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis | New England Journal of Medicine www.nejm.org/doi/full/10....

Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial | NEJM The cytokine A proliferation-inducing ligand (APRIL) is considered a key driver of the pathogenesis of IgA nephropathy. Sibeprenlimab, a humanized IgG2 monoclonal antibody, selectively binds to and...

Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial | New England Journal of Medicine www.nejm.org/doi/full/10....

A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy | NEJM IgA nephropathy, the most common primary glomerulopathy worldwide, is a kidney disorder of B-cell origin characterized by mesangial accumulation of IgA-containing immune complexes. In at least 50% ...

A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy | New England Journal of Medicine www.nejm.org/doi/full/10....

New insights in the pathophysiology and treatment of hypertension in autosomal dominant polycystic kidney disease Hypertension is a frequent and early manifestation in autosomal dominant polycystic kidney disease, significantly associated with kidney function decline and cardiovascular outcomes. Autosomal dominan...

New insights in the pathophysiology and treatment of hypertension in autosomal dominant polycystic kidney disease - Kidney International www.kidney-international.org/article/S008...

Predicting Prognosis in ANCA-Associated Vasculitis with Kidney Involvement AbstractIntroduction. The ANCA Renal Risk Score was revised in 2023 to improve clinico-pathological prognostication in patients with ANCA-associated vascul

Predicting Prognosis in ANCA-Associated Vasculitis with Kidney Involvement url: academic.oup.com/ckj/article/...

Changing from the CKD-EPI to the EKFC creatinine equation to estimate glomerular filtration rate in adults in a Northern European health system AbstractBackground. The European Kidney Function Consortium (EKFC) 2021 equation to estimate GFR performs as well or better than the CKD-EPI 2009 equation

1/9🚨 Changing one formula could make 38% more people “have CKD” overnight.
That’s what happens if we replace the CKD-EPI equation with EKFC in a European health system.
👉 Our @ndt-era.bsky.social paper shorturl.at/T5Dui
@delanaye.bsky.social
#NephSky #nephrology #EKFC #eGFR

Leading…lupus nephritis?

Collapsing GP?

Listen @chauvet-sophie.bsky.social on #ERA25

@stevengneph.bsky.social on fire in #ERA25-Nice talk about TMA and cancer

Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury (CP-AKI) from @kdjhaveri.bsky.social
#Nephpearls #Onconephrology 🦀 #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/40272825/

Kidney disease is a worldwide killer. Treat it that way The international community has a golden opportunity to start reining in the escalating, mostly ignored global burden of chronic kidney disease.

Kidney disease should be recognised on WHO's priority list of non-communicable diseases, alongside cancer, cardiovascular disease, and diabetes

https://go.nature.com/4lLJ5iY

We are waiting the results of OBILUP, which is currently underway!

Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis | NEJM Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving stan...

Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis | New England Journal of Medicine www.nejm.org/doi/full/10....

MPGN? Cryo?

Wonderful new study from @arkanalabs.bsky.social on the value of MPO IHC in crescentic GN with immune complexes; especially MN. Likely single disease process. Also may be useful tool to exclude endocarditis related GN in this setting. www.kireports.org/article/S246... #renalpath #pathsky #nephsky

🌍 Aujourd'hui, nous fêtons la Journée Mondiale du Rein !
Dans le cadre de sa mission, la SFNDT - Société Francophone de Néphrologie, Dialyse et Transplantation souligne l'importance de mieux connaître les maladies rénales et comment les dépister.
#WorldKidneyDay #AreYourKidneysOK

Early and Sensitive Detection of #Cisplatin Induced #KidneyInjury Using Novel #Biomarkers

#VisualAbstract by @jmteakell

www.kireports.org/ar...

#KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease ( #ADPKD): executive summary

doi.org/10.1016/j.kint.2024.07.010

#OpenAccess #clinicalpracticeguideline #kidney

Thank you for your comment. You're right, we wanted to illustrate that GFR estimation in oncology is not always reliable with CysC and that nephrologists need to measure GFR more often. This case reinforced the idea of the first case where selpercatinib also altered tubular creatine transport.

More on Selpercatinib and Pseudo-Decreases in Kidney Function | NEJM To the Editor: In their letter to the Editor, Izzedine et al. (April 4 issue)1 propose the measurement of cystatin C to estimate kidney function in a patient treated with selpercatinib who had a de...

www.nejm.org/doi/full/10....

Infection associated GN ?